Company: CRNX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001658247-25-000019
Chunk: 20

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
 lease expense2,360 2,283 Accretion of purchase discounts and amortization of premiums on investment securities, net(12,691)(10,768)Loss on disposal of property and equipment42 51 Loss on equity method investment— 470 Changes in operating assets and liabilities:Prepaid expenses and other assets(18,531)1,830 Accounts payable and accrued expenses, compensation and related expenses, and other liabilities17,807 7,201 Deferred revenue(1,128)74 Operating lease liabilities(2,578)811 Net cash used in operating activities(285,021)(163,323)CASH FLOWS FROM INVESTING ACTIVITIESPurchases of investment securities(790,781)(421,744)Proceeds from sales and maturities of investment securities912,886 391,830 Purchases of property and equipment(5,304)(2,815)Net cash provided by (used in) investing activities116,801 (32,729)CASH FLOWS FROM FINANCING ACTIVITIESProceeds from issuance of common stock, net of commissions— 441,498 Offering costs related to issuance of common stock— (15,949)Proceeds from exercise of stock options and shares issued under Employee Stock Purchase Plan14,576 32,875 Net cash provided by financing activities14,576 458,424 NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH(153,644)262,372 CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD265,845 56,197 CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD$112,201 $318,569 COMPONENTS OF CASH, CASH EQUIVALENTS AND RESTRICTED CASHCash and cash equivalents$110,901 $317,269 Restricted cash1,300 1,300 Cash, cash equivalents and restricted cash at end of period$112,201 $318,569 NONCASH INVESTING AND FINANCING ACTIVITIESStock options exercised receivable$4,737 $10 Receivable for common stock issuances$— $1,651 Amounts accrued for purchases of property and equipment$57 $62 Stock held in trust$112